Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs
A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples o...
Saved in:
Published in | International journal of pharmaceutics Vol. 438; no. 1-2; pp. 53 - 60 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
15.11.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples of two research compounds. The novel process is utilized N,N-dimethylacetamide (DMA) to dissolve the drug and the selected ionic polymer. This solution is then co-precipitated into aqueous medium. The solvent is extracted out by washing and the co-precipitated material is isolated by filtration followed by drying. The dried material is referred to as microprecipitated bulk powder (MBP). The amorphous form prepared using this method not only provides excellent in vitro and in vivo performance but also showed excellent stability. The stabilization of amorphous dispersion is attributed to the high Tg, ionic nature of the polymer that help to stabilize the amorphous form by possible ionic interactions, and/or due to the insolubility of polymer in water. In addition to being an alternate technology for amorphous formulation of difficult compounds, MBP technology provides advantages with respect to stability, density and downstream processing. |
---|---|
AbstractList | A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples of two research compounds. The novel process is utilized N,N-dimethylacetamide (DMA) to dissolve the drug and the selected ionic polymer. This solution is then co-precipitated into aqueous medium. The solvent is extracted out by washing and the co-precipitated material is isolated by filtration followed by drying. The dried material is referred to as microprecipitated bulk powder (MBP). The amorphous form prepared using this method not only provides excellent in vitro and in vivo performance but also showed excellent stability. The stabilization of amorphous dispersion is attributed to the high Tg, ionic nature of the polymer that help to stabilize the amorphous form by possible ionic interactions, and/or due to the insolubility of polymer in water. In addition to being an alternate technology for amorphous formulation of difficult compounds, MBP technology provides advantages with respect to stability, density and downstream processing. A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples of two research compounds. The novel process is utilized N,N-dimethylacetamide (DMA) to dissolve the drug and the selected ionic polymer. This solution is then co-precipitated into aqueous medium. The solvent is extracted out by washing and the co-precipitated material is isolated by filtration followed by drying. The dried material is referred to as microprecipitated bulk powder (MBP). The amorphous form prepared using this method not only provides excellent in vitro and in vivo performance but also showed excellent stability. The stabilization of amorphous dispersion is attributed to the high T(g), ionic nature of the polymer that help to stabilize the amorphous form by possible ionic interactions, and/or due to the insolubility of polymer in water. In addition to being an alternate technology for amorphous formulation of difficult compounds, MBP technology provides advantages with respect to stability, density and downstream processing. |
Author | Phuapradit, Wantanee Shah, Navnit Tang, Kin Choi, Duk Soon Albano, Antonio Chatterji, Ashish Malick, Waseem Iyer, Raman Pinal, Rodolfo Anand, Shalini Singhal, Dharmendra Tian, Hung Sandhu, Harpreet Chokshi, Hitesh |
Author_xml | – sequence: 1 givenname: Navnit surname: Shah fullname: Shah, Navnit organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 2 givenname: Harpreet surname: Sandhu fullname: Sandhu, Harpreet email: Harpreet_K.sandhu@roche.com organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 3 givenname: Wantanee surname: Phuapradit fullname: Phuapradit, Wantanee organization: Kashiv Pharma, Piscataway, NJ, USA – sequence: 4 givenname: Rodolfo surname: Pinal fullname: Pinal, Rodolfo organization: Purdue University, Lafayette, IN, USA – sequence: 5 givenname: Raman surname: Iyer fullname: Iyer, Raman organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 6 givenname: Antonio surname: Albano fullname: Albano, Antonio organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 7 givenname: Ashish surname: Chatterji fullname: Chatterji, Ashish organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 8 givenname: Shalini surname: Anand fullname: Anand, Shalini organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 9 givenname: Duk Soon surname: Choi fullname: Choi, Duk Soon organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 10 givenname: Kin surname: Tang fullname: Tang, Kin organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 11 givenname: Hung surname: Tian fullname: Tian, Hung organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 12 givenname: Hitesh surname: Chokshi fullname: Chokshi, Hitesh organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 13 givenname: Dharmendra surname: Singhal fullname: Singhal, Dharmendra organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA – sequence: 14 givenname: Waseem surname: Malick fullname: Malick, Waseem organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22974525$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkctu1DAUhi1URKeFRwC8LIsEXxI7WSEoV6kIJOjacuyTGQ9JnNpO0TwDL42jGdjWC1uWvvOfo_NdoLPJT4DQc0pKSqh4vS_dft7pMJaMUFaSpiScPkIb2khe8EqKM7QhXDZFTSU_Rxcx7gkhglH-BJ0z1sqqZvUG_XkP9zD4eYQpYd_jyecvHp0Jfg5g3OySTmBxtwy_8Ox_Wwj46uu7769wArOb_OC3B9z7gEc9Lb02aQlu2uKYdDcA1qMP884vcUXGZdDJ-SmufWbvw3DA0Q_LCtqwbONT9LjXQ4Rnp_cS3X788PP6c3Hz7dOX67c3hakYS0XNuTAgrBBtI9tK8AryZUzf6r7SQoIFaXknwBJmjNYNyI4DFxVv287qll-iq2PuHPzdAjGp0UUDw6AnyLMqmsGW8KaiD6P5NKJikmS0PqJ5dTEG6NUc3KjDQVGiVmVqr07K1KpMkUZlZbnuxanF0o1g_1f9c5SBl0eg117pbXBR3f7ICTXJKTWTK_HmSEDe2r2DoKJxMBmwLjtMynr3wBB_ASqDuOw |
CitedBy_id | crossref_primary_10_1016_j_ijpharm_2017_10_051 crossref_primary_10_1021_jm401329s crossref_primary_10_1080_17425247_2016_1198769 crossref_primary_10_1002_jps_24541 crossref_primary_10_1016_j_ijpharm_2022_122043 crossref_primary_10_1016_j_ijpharm_2020_119836 crossref_primary_10_1021_acs_oprd_1c00380 crossref_primary_10_1007_s11095_022_03308_9 crossref_primary_10_1111_jphp_12984 crossref_primary_10_3390_pharmaceutics13122017 crossref_primary_10_1016_j_ijpharm_2020_119560 crossref_primary_10_1016_S1773_2247_13_50057_8 crossref_primary_10_1080_03639045_2018_1562467 crossref_primary_10_1208_s12249_018_0988_1 crossref_primary_10_1016_j_ijpharm_2015_03_053 crossref_primary_10_1016_j_xphs_2023_02_012 crossref_primary_10_1016_j_ajps_2023_100834 crossref_primary_10_1016_j_xphs_2022_09_007 crossref_primary_10_1016_j_xphs_2023_02_011 crossref_primary_10_1208_s12249_015_0395_9 crossref_primary_10_1016_j_ijpharm_2017_04_007 crossref_primary_10_1208_s12249_018_1007_2 crossref_primary_10_1002_crat_202300296 crossref_primary_10_1208_s12249_015_0393_y crossref_primary_10_2174_1381612826666200701134135 crossref_primary_10_1016_j_ejca_2022_06_031 crossref_primary_10_1016_j_ijpharm_2013_04_040 crossref_primary_10_1016_j_ijpharm_2015_08_016 crossref_primary_10_1016_j_ijpharm_2014_08_016 crossref_primary_10_1016_S1773_2247_14_50033_0 crossref_primary_10_3109_03639045_2015_1075031 crossref_primary_10_1016_j_ijpharm_2021_121216 crossref_primary_10_2139_ssrn_4065567 crossref_primary_10_3390_polym12081679 crossref_primary_10_3109_03639045_2015_1018274 crossref_primary_10_1007_s40005_022_00568_w crossref_primary_10_1016_j_xphs_2023_02_005 crossref_primary_10_1016_j_xphs_2021_02_004 crossref_primary_10_1016_j_ejpb_2013_03_013 crossref_primary_10_1016_j_ejpb_2013_09_007 crossref_primary_10_3390_pharmaceutics13071034 crossref_primary_10_1016_j_ijpx_2024_100259 crossref_primary_10_1016_j_xphs_2017_07_001 crossref_primary_10_1021_acs_molpharmaceut_2c00456 crossref_primary_10_1208_s12249_017_0861_7 crossref_primary_10_1021_acs_molpharmaceut_0c00198 crossref_primary_10_1016_j_ejps_2017_06_019 crossref_primary_10_1016_j_xphs_2020_12_033 crossref_primary_10_1007_s13346_018_0494_8 crossref_primary_10_1016_j_ijpharm_2019_01_009 crossref_primary_10_1111_jphp_12805 crossref_primary_10_1208_s12249_018_1082_4 crossref_primary_10_1016_j_ijpharm_2013_05_061 crossref_primary_10_3390_ma16206616 crossref_primary_10_1021_acs_molpharmaceut_8b00125 |
Cites_doi | 10.1016/S0378-5173(02)00173-4 10.1016/S0939-6411(00)00076-X 10.1021/mp8000793 10.1016/j.ijpharm.2011.08.007 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10 10.1021/mp8001073 10.1200/JCO.2004.12.007 10.1021/mp9002283 10.1039/c001905d 10.1248/cpb.9.866 10.1002/jps.2600800820 10.1007/s11095-009-9970-7 10.1021/mp0700211 10.1016/S0378-5173(02)00331-9 10.1111/j.2042-7158.2003.tb02431.x 10.1016/j.ijpharm.2007.12.017 10.1081/DDC-120030422 |
ContentType | Journal Article |
Copyright | 2012 Elsevier B.V. Copyright © 2012 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2012 Elsevier B.V. – notice: Copyright © 2012 Elsevier B.V. All rights reserved. |
DBID | FBQ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QO 8FD FR3 P64 |
DOI | 10.1016/j.ijpharm.2012.08.031 |
DatabaseName | AGRIS Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE - Academic MEDLINE Engineering Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-3476 |
EndPage | 60 |
ExternalDocumentID | 10_1016_j_ijpharm_2012_08_031 22974525 US201500125275 S0378517312008265 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AATCM AAXUO ABFNM ABFRF ABJNI ABMAC ABOCM ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HZ~ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SCC SDF SDG SDP SES SPCBC SSP SSZ T5K TEORI ~02 ~G- .GJ 29J 3O- 53G AAQXK ABPIF ABPTK ASPBG AVWKF AZFZN FBQ FEDTE FGOYB G-2 HMT HVGLF R2- SEW SPT WUQ ZXP AAXKI AKRWK CGR CUY CVF ECM EIF NPM AAYXX AFJKZ CITATION 7X8 7QO 8FD FR3 P64 |
ID | FETCH-LOGICAL-c422t-5336ce6d6698794634e463ccf9af4a67ede7d3b6ed02ccaa8e7b3e364399bda93 |
IEDL.DBID | AIKHN |
ISSN | 0378-5173 |
IngestDate | Fri Oct 25 03:20:53 EDT 2024 Sat Oct 05 05:47:08 EDT 2024 Thu Sep 26 16:59:30 EDT 2024 Sat Sep 28 08:05:44 EDT 2024 Wed Dec 27 18:58:14 EST 2023 Fri Feb 23 02:20:35 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1-2 |
Keywords | EPK SCP HME Amorphous DMA Solid dispersion MBP PK Solid solution MAP Co-precipitation PXRD |
Language | English |
License | Copyright © 2012 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c422t-5336ce6d6698794634e463ccf9af4a67ede7d3b6ed02ccaa8e7b3e364399bda93 |
Notes | http://dx.doi.org/10.1016/j.ijpharm.2012.08.031 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 22974525 |
PQID | 1111864270 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1399903841 proquest_miscellaneous_1111864270 crossref_primary_10_1016_j_ijpharm_2012_08_031 pubmed_primary_22974525 fao_agris_US201500125275 elsevier_sciencedirect_doi_10_1016_j_ijpharm_2012_08_031 |
PublicationCentury | 2000 |
PublicationDate | 2012-11-15 |
PublicationDateYYYYMMDD | 2012-11-15 |
PublicationDate_xml | – month: 11 year: 2012 text: 2012-11-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | International journal of pharmaceutics |
PublicationTitleAlternate | Int J Pharm |
PublicationYear | 2012 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Kislalioglu, Khan, Blount, Goettsch, Bolton (bib0050) 1991; 80 Maniruzzaman, Rana, Boateng, Mitchell, Douroumis (bib0070) 2012 Rumondor, Ivanisevic, Bates, Alonzo, Taylor (bib0075) 2009; 26 Matteucci, Brettmann, Rogers, Elder, Williams, Johnson (bib0065) 2007; 4 Albano A. Phuapradit W. Sandhu H., Shah N., 2002. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability. US Patent 6486329. Sekiguchi, Obi (bib0085) 1961; 29 Leuner, Dressman (bib0060) 2000; 50 Sertsou, Butler, Scott, Hempenstall, Rades (bib0090) 2002; 245 Habib (bib0025) 2001 Hughey, Keen, Brough, Saeger, McGinity (bib0035) 2011; 419 Dupont, Bienvenu, Aghajanian, Pezzuli, Sabbatini, Vongphrachanh, Chang, Perkell, Ng, Passe, Briemer, Zhi, DeMario, Spriggs, Soignet (bib0020) 2004; 22 Lakshman, Cao, Kowalski, Serajuddin (bib0055) 2008; 5 Sertsou, Butler, Hempenstall, Rades (bib0095) 2003; 55 Kestur, Taylor (bib0045) 2010; 12 Dong, Chatterji, Sandhu, Choi, Chokshi, Shah (bib0015) 2008; 355 Hu, Johnston, Williams (bib0030) 2004; 30 Rumondor, Taylor (bib0080) 2010; 7 Cilurzo, Minghetti, Casiraghi, Montanari (bib0010) 2002; 242 Friesen, Shankar, Crew, Smithey, Curatolo, Nightangle (bib0105) 2008; 5 Kaushal, Gupta, Bansal (bib0040) 2004; 21 Cilurzo (10.1016/j.ijpharm.2012.08.031_bib0010) 2002; 242 Kaushal (10.1016/j.ijpharm.2012.08.031_bib0040) 2004; 21 Rumondor (10.1016/j.ijpharm.2012.08.031_bib0075) 2009; 26 Dong (10.1016/j.ijpharm.2012.08.031_bib0015) 2008; 355 10.1016/j.ijpharm.2012.08.031_bib0100 Hu (10.1016/j.ijpharm.2012.08.031_bib0030) 2004; 30 Kislalioglu (10.1016/j.ijpharm.2012.08.031_bib0050) 1991; 80 Lakshman (10.1016/j.ijpharm.2012.08.031_bib0055) 2008; 5 Kestur (10.1016/j.ijpharm.2012.08.031_bib0045) 2010; 12 Hughey (10.1016/j.ijpharm.2012.08.031_bib0035) 2011; 419 Friesen (10.1016/j.ijpharm.2012.08.031_bib0105) 2008; 5 Sekiguchi (10.1016/j.ijpharm.2012.08.031_bib0085) 1961; 29 Sertsou (10.1016/j.ijpharm.2012.08.031_bib0095) 2003; 55 Maniruzzaman (10.1016/j.ijpharm.2012.08.031_bib0070) 2012 Rumondor (10.1016/j.ijpharm.2012.08.031_bib0080) 2010; 7 Dupont (10.1016/j.ijpharm.2012.08.031_bib0020) 2004; 22 Leuner (10.1016/j.ijpharm.2012.08.031_bib0060) 2000; 50 Habib (10.1016/j.ijpharm.2012.08.031_bib0025) 2001 Matteucci (10.1016/j.ijpharm.2012.08.031_bib0065) 2007; 4 Sertsou (10.1016/j.ijpharm.2012.08.031_bib0090) 2002; 245 |
References_xml | – volume: 5 start-page: 994 year: 2008 end-page: 1002 ident: bib0055 article-title: Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug publication-title: Mol. Pharm. contributor: fullname: Serajuddin – volume: 26 start-page: 2523 year: 2009 end-page: 2535 ident: bib0075 article-title: Evaluation of drug–polymer miscibility in amorphous solid dispersion systems publication-title: Pharm. Res. contributor: fullname: Taylor – volume: 21 start-page: 133 year: 2004 end-page: 193 ident: bib0040 article-title: Amorphous drug delivery systems: molecular aspects, design and performance publication-title: Crit. Rev. Ther. Drug Carrier Syst. contributor: fullname: Bansal – volume: 355 start-page: 141 year: 2008 end-page: 149 ident: bib0015 article-title: Evaluation of solid state properties of solid dispersions prepared by hot–melt extrusion and solvent co-precipitation publication-title: Int. J. Pharm. contributor: fullname: Shah – volume: 242 start-page: 313 year: 2002 end-page: 317 ident: bib0010 article-title: Characterization of nifedipine solid dispersions publication-title: Int. J. Pharm. contributor: fullname: Montanari – volume: 29 start-page: 866 year: 1961 end-page: 867 ident: bib0085 article-title: New solid state dispersions for increasing dissolution rates publication-title: Chem. Pharm. Bull. contributor: fullname: Obi – volume: 245 start-page: 99 year: 2002 end-page: 108 ident: bib0090 article-title: Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation publication-title: Int. J. Pharm. contributor: fullname: Rades – year: 2001 ident: bib0025 article-title: Fundamentals of Solid Dispersions contributor: fullname: Habib – volume: 12 start-page: 2390 year: 2010 end-page: 2397 ident: bib0045 article-title: Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine publication-title: Cryst. Eng. Comm. contributor: fullname: Taylor – volume: 30 start-page: 233 year: 2004 end-page: 245 ident: bib0030 article-title: Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs publication-title: Drug Dev. Ind. Pharm. contributor: fullname: Williams – volume: 4 start-page: 782 year: 2007 end-page: 793 ident: bib0065 article-title: Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media publication-title: Mol. Pharm. contributor: fullname: Johnson – volume: 7 start-page: 477 year: 2010 end-page: 490 ident: bib0080 article-title: Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture publication-title: Mol. Pharm. contributor: fullname: Taylor – volume: 55 start-page: 35 year: 2003 end-page: 41 ident: bib0095 article-title: Physical stability and enthalpy relaxation of drug–hypromellose phthalate solvent change co-precipitates publication-title: J. Pharm. Pharmacol. contributor: fullname: Rades – volume: 50 start-page: 47 year: 2000 end-page: 60 ident: bib0060 article-title: Improving drug solubility for oral delivery using solid dispersions publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Dressman – year: 2012 ident: bib0070 article-title: Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers publication-title: Drug Dev. Ind. Pharm. contributor: fullname: Douroumis – volume: 419 start-page: 222 year: 2011 end-page: 230 ident: bib0035 article-title: Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol publication-title: Int. J. Pharm. contributor: fullname: McGinity – volume: 80 start-page: 799 year: 1991 end-page: 804 ident: bib0050 article-title: Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates publication-title: J. Pharm. Sci. contributor: fullname: Bolton – volume: 22 start-page: 3366 year: 2004 end-page: 3376 ident: bib0020 article-title: Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors publication-title: J. Clin. Oncol. contributor: fullname: Soignet – volume: 5 start-page: 1003 year: 2008 end-page: 1019 ident: bib0105 article-title: Hydroxypropyl methylcellulose Acetate Succinate-Based Spray Dried Dispersions: An Overview publication-title: Mol. Pharm. contributor: fullname: Nightangle – volume: 242 start-page: 313 year: 2002 ident: 10.1016/j.ijpharm.2012.08.031_bib0010 article-title: Characterization of nifedipine solid dispersions publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(02)00173-4 contributor: fullname: Cilurzo – volume: 50 start-page: 47 year: 2000 ident: 10.1016/j.ijpharm.2012.08.031_bib0060 article-title: Improving drug solubility for oral delivery using solid dispersions publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/S0939-6411(00)00076-X contributor: fullname: Leuner – volume: 5 start-page: 1003 issue: 6 year: 2008 ident: 10.1016/j.ijpharm.2012.08.031_bib0105 article-title: Hydroxypropyl methylcellulose Acetate Succinate-Based Spray Dried Dispersions: An Overview publication-title: Mol. Pharm. doi: 10.1021/mp8000793 contributor: fullname: Friesen – ident: 10.1016/j.ijpharm.2012.08.031_bib0100 – volume: 419 start-page: 222 year: 2011 ident: 10.1016/j.ijpharm.2012.08.031_bib0035 article-title: Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol® dispersing publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2011.08.007 contributor: fullname: Hughey – volume: 21 start-page: 133 year: 2004 ident: 10.1016/j.ijpharm.2012.08.031_bib0040 article-title: Amorphous drug delivery systems: molecular aspects, design and performance publication-title: Crit. Rev. Ther. Drug Carrier Syst. doi: 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10 contributor: fullname: Kaushal – year: 2001 ident: 10.1016/j.ijpharm.2012.08.031_bib0025 contributor: fullname: Habib – volume: 5 start-page: 994 year: 2008 ident: 10.1016/j.ijpharm.2012.08.031_bib0055 article-title: Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug publication-title: Mol. Pharm. doi: 10.1021/mp8001073 contributor: fullname: Lakshman – volume: 22 start-page: 3366 year: 2004 ident: 10.1016/j.ijpharm.2012.08.031_bib0020 article-title: Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2004.12.007 contributor: fullname: Dupont – volume: 7 start-page: 477 year: 2010 ident: 10.1016/j.ijpharm.2012.08.031_bib0080 article-title: Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture publication-title: Mol. Pharm. doi: 10.1021/mp9002283 contributor: fullname: Rumondor – year: 2012 ident: 10.1016/j.ijpharm.2012.08.031_bib0070 article-title: Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers publication-title: Drug Dev. Ind. Pharm. contributor: fullname: Maniruzzaman – volume: 12 start-page: 2390 year: 2010 ident: 10.1016/j.ijpharm.2012.08.031_bib0045 article-title: Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine publication-title: Cryst. Eng. Comm. doi: 10.1039/c001905d contributor: fullname: Kestur – volume: 29 start-page: 866 year: 1961 ident: 10.1016/j.ijpharm.2012.08.031_bib0085 article-title: New solid state dispersions for increasing dissolution rates publication-title: Chem. Pharm. Bull. doi: 10.1248/cpb.9.866 contributor: fullname: Sekiguchi – volume: 80 start-page: 799 year: 1991 ident: 10.1016/j.ijpharm.2012.08.031_bib0050 article-title: Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600800820 contributor: fullname: Kislalioglu – volume: 26 start-page: 2523 year: 2009 ident: 10.1016/j.ijpharm.2012.08.031_bib0075 article-title: Evaluation of drug–polymer miscibility in amorphous solid dispersion systems publication-title: Pharm. Res. doi: 10.1007/s11095-009-9970-7 contributor: fullname: Rumondor – volume: 4 start-page: 782 year: 2007 ident: 10.1016/j.ijpharm.2012.08.031_bib0065 article-title: Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media publication-title: Mol. Pharm. doi: 10.1021/mp0700211 contributor: fullname: Matteucci – volume: 245 start-page: 99 year: 2002 ident: 10.1016/j.ijpharm.2012.08.031_bib0090 article-title: Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(02)00331-9 contributor: fullname: Sertsou – volume: 55 start-page: 35 year: 2003 ident: 10.1016/j.ijpharm.2012.08.031_bib0095 article-title: Physical stability and enthalpy relaxation of drug–hypromellose phthalate solvent change co-precipitates publication-title: J. Pharm. Pharmacol. doi: 10.1111/j.2042-7158.2003.tb02431.x contributor: fullname: Sertsou – volume: 355 start-page: 141 year: 2008 ident: 10.1016/j.ijpharm.2012.08.031_bib0015 article-title: Evaluation of solid state properties of solid dispersions prepared by hot–melt extrusion and solvent co-precipitation publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.12.017 contributor: fullname: Dong – volume: 30 start-page: 233 year: 2004 ident: 10.1016/j.ijpharm.2012.08.031_bib0030 article-title: Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs publication-title: Drug Dev. Ind. Pharm. doi: 10.1081/DDC-120030422 contributor: fullname: Hu |
SSID | ssj0006213 |
Score | 2.3824046 |
Snippet | A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray... |
SourceID | proquest crossref pubmed fao elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 53 |
SubjectTerms | Acetamides - chemistry Amorphous Animals Antineoplastic Agents - blood Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics Co-precipitation coprecipitation Dogs Drug Compounding - methods drugs extrusion filtration manufacturing MBP melting methodology Pharmaceutical Preparations - chemistry polymers Polymers - chemistry Powders - chemistry Powders - pharmacokinetics Rats Solid dispersion Solid solution Solubility solvents spray drying washing |
Title | Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs |
URI | https://dx.doi.org/10.1016/j.ijpharm.2012.08.031 https://www.ncbi.nlm.nih.gov/pubmed/22974525 https://search.proquest.com/docview/1111864270 https://search.proquest.com/docview/1399903841 |
Volume | 438 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZN-rKXsXuzS9FglA3qxJZk2Xrsykq2sRJoA30zkiWXpIltkpiRl_2B_emd40uyPXSDvRhkS1jSOTr6jnQuhLxLw5QZxWAh8Uh4ItCpF2dZ4ClplLZpBiiiNpC9lOOp-HIT3hyQ884XBs0qW9nfyPRaWrdvRu1sjsrZbHTl8zqxPA_wCp_JsEcOYTticZ8cnn3-Or7cCWTJ2izJoDBhg70jz2g-nM1LjBGNRl6sDubJg_u2qF6mi_uBaL0hXTwiD1skSc-azj4mBy5_Qk4mTSjq7Sm93ntWrU_pCZ3sg1Rvn5Kfv1kL0SKjeQFFukTzvBIDXmAyEQCj1FSLO1oW361b0fffPk4-0M3uMJ4C4KVLnVfoHVG7O1LAmmbhqF4WQL-iWmOVZZshbI3_KYtitdhS5HisaFfV7foZmV58uj4fe21iBi8VjG08gIgyddJKqWIMUM-Fg0eaZkpnQsvIWRdZbqSzPgMO0bGLDHccwY8yViv-nPTzIndHhLJIxQCqTKgFF1JYFYG2bnwnmY58G2QDMuxokZRN_I2kM0ybJy3xEiReguk0eTAgcUex5A9GSmCP-FfTI6Bwom9BvCbTK4aHQfA1ZFE4IG87siew_vBSRecOprHWoGJQ4iL_L3Vg3MrnsYBfvGh4ZjcYxkCjC1n48v_7_Yo8wBJ6SAbha9LfrCr3BqDSxhyT3vBHcNwuiF-RqhSC |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBa9PGwvo7s2u2owygZ1Y0uybD12ZSVd2xBoAn0Tki2XZIltkpiS37A_vXMcO9keusFeDLYkLOkcHX1HOhdCPiVhwqxisJB4JDwRmMSLsyzwlLTKpEkGKKI2kO3L3kh8vw1vd8hZ6wuDZpWN7F_L9FpaN1-6zWx2y_G4e-PzOrE8D_AKn8lwl-wDGlCwOvdPLy57_Y1AlqzJkgwKEzbYOvJ0JyfjSYkxotHIi9XBPHnw0Ba1m5niYSBab0jnB-RJgyTp6bqzT8mOy5-Ro8E6FPXqmA63nlWLY3pEB9sg1avn5Odv1kK0yGhewCudoXleiQEvMJkIgFFqq-kPWhb3qZvTz9dfB1_ocnMYTwHw0pnJK_SOqN0dKWBNO3XUzAqgX1EtsMqsyRC2wP-URTGfrihyPFZM59Xd4gUZnX8bnvW8JjGDlwjGlh5ARJk4mUqpYgxQz4WDR5JkymTCyMilLkq5lS71GXCIiV1kueMIfpRNjeIvyV5e5O6QUBapGECVDY3gQopURaCtW99JZiI_DbIOOWlpoct1_A3dGqZNdEM8jcTTmE6TBx0StxTTfzCShj3iX00PgcLa3IF41aMbhodBUBqyKOyQjy3ZNaw_vFQxuYNprDWoGJS4yP9LHRi38nks4Bev1jyzGQxjoNGFLHz9__3-QB71htdX-uqif_mGPMYS9JYMwrdkbzmv3DuATUv7vlkWvwA-2BZ2 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+novel+microprecipitated+bulk+powder+%28MBP%29+technology+for+manufacturing+stable+amorphous+formulations+of+poorly+soluble+drugs&rft.jtitle=International+journal+of+pharmaceutics&rft.au=Shah%2C+Navnit&rft.au=Sandhu%2C+Harpreet&rft.au=Phuapradit%2C+Wantanee&rft.au=Pinal%2C+Rodolfo&rft.date=2012-11-15&rft.pub=Elsevier+B.V&rft.issn=0378-5173&rft.eissn=1873-3476&rft.volume=438&rft.issue=1-2&rft.spage=53&rft.epage=60&rft_id=info:doi/10.1016%2Fj.ijpharm.2012.08.031&rft.externalDocID=S0378517312008265 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5173&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5173&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5173&client=summon |